Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Complementary Medicines
Therapeutic Methods and Therapies TCIM
Database
Language
Publication year range
1.
Medicine (Baltimore) ; 103(11): e37534, 2024 Mar 15.
Article in English | MEDLINE | ID: mdl-38489714

ABSTRACT

BACKGROUND: Local anesthetic systemic toxicity (LAST) is rare, but fatal; the current widely used treatment is lipid emulsion (LE). The goal of this study was to analyze and review case reports on LE treatment for LAST in pediatric patients. METHODS: We performed a systematic review using case reports on LE treatment for LAST in pediatric patients, searching PubMed and Scopus databases to March 2023 using the following keywords: ("local anesthetic toxicity" OR "local anesthetic systemic toxicity" OR LAST") AND ("newborn" OR "infant" OR "child" OR "children" OR "adolescent" OR "pediatric") AND ("lipid emulsion" OR "Intralipid"). RESULTS: Our search yielded 21 cases, revealing that nearly 43% patients with LAST were less than 1 year old, and most cases were caused by bupivacaine (approximately 67% cases). "Inadvertent intravascular injection" by anesthesiologists and "overdose of local anesthetics" mainly by surgeons were responsible for 52% and 24% cases of LAST, respectively. LAST occurred in the awake state (52%) and under general anesthesia (48%), mainly causing seizures and arrhythmia, respectively. Approximately 55% of patients received LE treatment in <10 minutes after LAST, mainly improving cardiovascular symptoms. A 20% LE (1.5 mL/kg) dose followed by 0.25 mL/kg/minutes dose was frequently used. LE and anticonvulsants were mainly used in the awake state, whereas LE with or without vasopressors was mainly used under general anesthesia. LE treatment led to full recovery from LAST in 20 cases; however, 1 patient died due to underlying disease. CONCLUSION: Consequently, our findings reveal that LE is effective in treating pediatric LAST.


Subject(s)
Anesthetics, Local , Fat Emulsions, Intravenous , Humans , Anesthetics, Local/adverse effects , Anesthetics, Local/administration & dosage , Fat Emulsions, Intravenous/therapeutic use , Fat Emulsions, Intravenous/administration & dosage , Child , Infant , Child, Preschool , Adolescent , Bupivacaine/adverse effects , Bupivacaine/administration & dosage , Infant, Newborn , Female , Male
2.
Medicine (Baltimore) ; 97(42): e12866, 2018 Oct.
Article in English | MEDLINE | ID: mdl-30334999

ABSTRACT

RATIONALE: Hepatocellular carcinomas (HCCs) with metastases to the right atrium (RA) and lungs are rare, with a poor prognosis. Furthermore, the treatment outcomes in patients with advanced HCCs remain unsatisfactory. PATIENT CONCERNS: A 46-year-old man presented to our hospital for dyspnea on exertion and abdominal pain. DIAGNOSES: HCC and extra-hepatic metastases to the lung and RA. INTERVENTIONS: Multidisciplinary treatment including radiotherapy (RT), transarterial chemoembolization (TACE), and sorafenib. During a follow-up evaluation computed tomography, he experienced a radio-contrast-induced anaphylaxis. After the event, treatment such as RT, TACE, and sorafenib were continued. OUTCOMES: His tumor burden decreased, finally leading to a complete response as per the modified Response Evaluation Criteria in Solid Tumors. The patient is still alive, 30 months after the episode. Subsequent blood tests showed increased natural killer (NK) cell activity, which was significantly higher than that seen in other age-matched HCC patients with an identical stage of the tumor, receiving sorafenib. This suggests that the increase in NK cells induced by anaphylaxis influenced the tumor burden. LESSONS: We report here a rare case of long-term survival of an HCC patient with multiple metastases treated with multidisciplinary modalities, in which high NK cell activity was observed after a radio-contrast-induced anaphylactic reaction during follow-up investigations.


Subject(s)
Antineoplastic Protocols , Carcinoma, Hepatocellular/therapy , Heart Neoplasms/therapy , Liver Neoplasms/therapy , Lung Neoplasms/therapy , Antineoplastic Agents/administration & dosage , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/secondary , Chemoembolization, Therapeutic/methods , Combined Modality Therapy/methods , Heart Atria/pathology , Heart Neoplasms/pathology , Heart Neoplasms/secondary , Humans , Killer Cells, Natural/drug effects , Killer Cells, Natural/radiation effects , Liver Neoplasms/pathology , Lung/pathology , Lung Neoplasms/pathology , Lung Neoplasms/secondary , Male , Middle Aged , Niacinamide/administration & dosage , Niacinamide/analogs & derivatives , Phenylurea Compounds/administration & dosage , Radiotherapy, Adjuvant/methods , Remission Induction/methods , Response Evaluation Criteria in Solid Tumors , Sorafenib , Tumor Burden
SELECTION OF CITATIONS
SEARCH DETAIL